Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Argus Health
Federal Trade Commission
US Department of Justice
Harvard Business School
AstraZeneca

Generated: September 23, 2019

DrugPatentWatch Database Preview

Litigation Details for SUN PHARMACEUTICAL INDUSTRIES LIMITED v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

SUN PHARMACEUTICAL INDUSTRIES LIMITED v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)

Docket ➤ Sign Up Date Filed 2019-01-09
Court District Court, D. New Jersey Date Terminated
Cause 28:1331 Federal Question-Injunctive & Declaratory Relief Assigned To Susan Davis Wigenton
Jury Demand None Referred To Steven C. Mannion
Parties NOVARTIS AG; NOVARTIS PHARMACEUTICALS CORP.; SUN PHARMACEUTICAL INDUSTRIES LIMITED
Patents 6,465,504; 9,283,209
Attorneys GREGORY D. MILLER
Firms Rivkin Radler LLP
Link to Docket External link to docket
Small Molecule Drugs cited in SUN PHARMACEUTICAL INDUSTRIES LIMITED v. NOVARTIS PHARMACEUTICALS CORP.
The small molecule drugs covered by the patents cited in this case are ➤ Sign Up , ➤ Sign Up , and ➤ Sign Up .

Details for SUN PHARMACEUTICAL INDUSTRIES LIMITED v. NOVARTIS PHARMACEUTICALS CORP. (D.N.J. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-01-09 1 caused two patents to be listed in FDA’s Orange Book as covering Jadenu®: U.S. Patent No. 6,465,504 (“the …declaratory relief that Novartis’ U.S. Patent No. 9,283,209 (“the ‘209 patent”) is invalid, unenforceable and…action regarding allegations of patent infringement arising under the patent laws of the United States, Title…certifications for each patent listed in the Orange Book for the RLD: (i) there are no patents listed in the Orange… Orange Book; ii) any listed patent has expired; (iii) the patent will have expired before the generic External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Mallinckrodt
Medtronic
Harvard Business School
Daiichi Sankyo
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.